Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 8Cholangiocarcinoma 4Stomach Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Carcinoma, Non-Small-Cell Lung 3Biliary Tract Neoplasms 3Osteosarcoma 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumor 1Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic cancer, adult 1Pancreatic Cancer Metastatic 1Neuroendocrine Tumor Grade 3 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma 1Breast Neoplasms 1

Interventions

Everolimus 5Temozolomide 4sargramostim 2montanide ISA 51 2lutetium Lu 177 dotatate 2incomplete Freund's adjuvant 2Sunitinib 2Specimen Handling 2Sorafenib 2Octreotide 2Magnetic Resonance Spectroscopy 2Leucovorin 2Fluorouracil 2Cytoreduction Surgical Procedures 2Colony-Stimulating Factors 2Bevacizumab 2surufatinib 1recombinant interferon alpha 2b-like protein 1pentetreotide 1pasireotide 1nimotuzumab 1ibrutinib 1ganitumab 1gallium Ga 68 dotatate 1fludarabine phosphate 1cabozantinib 1atezolizumab 1abemaciclib 1Wound Healing 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenoma, Islet Cell × surufatinib × Clear all
NCT06158516 2023-12-06

A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

Changhai Hospital

Phase 2 Not yet recruiting
100 enrolled

Adenoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡